South Easton, MA -- (SBWire) -- 04/22/2015 --Taking a look at Pressure BioSciences, Inc., a leader in the development and sale of broadly enabling sample preparation solutions using their patented pressure cycling technology (or PCT) platform, they announced in February the award of over $1 million dollars in non-dilutive grant funding from the National Human Genome Research Institutes of the National Institutes of Health (NIH). The grant will help fund development of automated systems, enabling significantly better control of DNA fragmentation, which is a critical step in the preparation of samples for Next Generation Sequencing (NGS) Platforms. The award of this DNA grant offers Pressure BioSciences a rapid and affordable entrance into the expanding genomic marketplace. NGS is one of the fastest growing, multi-billion dollar segments of the life sciences, offering the promise of significant discoveries and improvements in human healthcare, particularly personalized medicine.

Last week Zacks Small-Cap Research released an updated report on the company. Not only did Zacks maintain their BUY rating on PBIO, the increased their 12-month Target Price to $3.00 per share. Zacks bullish stance on the Company appears grounded in sound reasoning. In 2014, the Company showed an increase of almost 30% in products and services revenue with substantial projected growth for 2015.

With the NIH grant and Zacks Small-Cap Research's shinning approval of Pressure BioSciences, it is clear to us that the company will be accelerating sales growth in 2015 and beyond. The Company's successful beta testing and launch of their Barozyme HT48 High-throughput PCT-based system, adds support to the expectation for even stronger revenue numbers in 2015. The Barozyme HT48 High-throughput System was evaluated independently at the end of 4th quarter 2014. The results were strong with the first purchase order received for the Barozyme HT48 System in February to a leading U.S. biotechnology company, which already owned and utilized two prior instrument models from Pressure BioSciences, the NEP 2320.

Zacks Small-Cap Research stated, "We think revenue ramp in 2015 will be driven by sales from both existing and new products (instruments and consumable), from the Company's expanding distribution network." Zacks also projects that Pressure BioSciences will achieve a twelve-month target price of $3.00 (April 6 closing price was $0.30). The Company has implemented strong goals for 2015, including expanded sales and marketing campaigns to reach into new countries, investigators, and fields-of-use. With strong 2014 numbers already in, a new $1 million grant, new cutting-edge instruments and consumables to complement existing products, planned expansion of sales and marketing capabilities, and users who include some of the key research scientists in the United States and worldwide, Pressure BioSciences is surging forward to attain what we believe will be far greater heights in 2015.

About Pressure BioSciences, Inc. (taken from publicly-released documents)
Pressure BioSciences, Inc. ("PBI") develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

For more information about Pressure BioSciences, Inc., please click on the following website link: http://www.pressurebiosciences.com

For information on the Zacks Small-Cap Research PBIO report please click the following: "PBIO Reports Record Product/Service Sales for Fiscal Year 2014"

For information on the Zacks Small-Cap Research full report on PBIO, please click the following here.

For more information on UPTICK Newswire, please click the following:
http://upticknewswire.com/